Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Jan Moritz Middeke, Felicitas Thol et al.|Blood Cancer Journal|2021Cited by 65
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trialClaudia M. Denkinger, Michael Schmitt, Maike Janssen et al.|Nature Cancer|2022Cited by 62
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patientsChristina Rautenberg, Friedrich Stölzel, Jan Moritz Middeke et al.|Blood Cancer Journal|2025Cited by 6
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialClaudia M. Denkinger, Michaël Schmitt, Maike Janssen et al.|medRxiv|2022Cited by 4
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid LeukemiaChristina Rautenberg, M. Middeke, Friedrich Stölzel et al.|Blood|2021Cited by 3